SCHEMBL4253236

SCHEMBL4253236

Cc1ccc(NC(=O)c2cc(N3CCN(CCO)CC3)cc(C(F)(F)F)c2)cc1C(N)=O

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BRAF P15056 9/20 0.54
RAF1 P04049 8/20 0.54
CSF1R P07333 5/20 0.54
LYN P07948 4/20 0.54
LCK P06239 4/20 0.51
KDR P35968 4/20 0.51
TEK Q02763 3/20 0.51
MAPK14 Q16539 2/20 0.51
NTRK1 P04629 1/20 0.51
NTRK2 Q16620 1/20 0.51
CHRM4 P08173 1/20 0.49
CHRM1 P11229 1/20 0.49
SRC P12931 3/20 0.47
ABL1 P00519 1/20 0.47
FYN P06241 1/20 0.47
MAPK9 P45984 1/20 0.47
INSR P06213 2/20 0.47
HCK P08631 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258210 0.91 RAF1 (0.60) BRAFRAF1CSF1RLYNLCK
SCHEMBL4257827 0.90 CSF1R (0.65) BRAFRAF1CSF1RLYNLCK
SCHEMBL4253241 0.89 BRAF (0.55) BRAFRAF1CSF1RLYNLCK
SCHEMBL4250368 0.84 CSF1R (0.65) BRAFRAF1CSF1RLYNLCK
SCHEMBL4256187 0.80 BRAF (0.63) BRAFRAF1CSF1RLYNLCK
SCHEMBL4257833 0.78 CSF1R (0.66) BRAFRAF1CSF1RLYNLCK
SCHEMBL4789368 0.77 BRAF (0.60) BRAFRAF1CSF1RLYNLCK
SCHEMBL4252903 0.77 CSF1R (0.66) BRAFRAF1CSF1RLYNLCK
SCHEMBL3585041 0.76 CSF1R (0.66) BRAFRAF1CSF1RLYNLCK
SCHEMBL4421970 0.76 CSF1R (0.55) BRAFCSF1RLCKKDRTEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US claimed
EP-1841431-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-10-10 EP claimed
WO-2006081172-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-08-03 WO claimed
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-23 US disclosed
EP-1841431-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-10-10 EP disclosed
WO-2006081172-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105250-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ABL1, BCR, PDGFRB BRAF 8/4885RAF1 10/4885CSF1R 891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.